Here’s Why JAGX Stock Is Headed Up
UPDATE: After digging further, we found that the report leading to the gains today was a paid advertisement. While paid advertisements are often used in the right ways, they are sometimes used in pump and dump scemes. Considering that the press release associated with this paid advertisement did not imply that the firm had been paid, there’s a storng chance that this is the case here. Be very careful if you play this run!
As mentioned above, Jaguar Health is having a great day in the market today. However, with no press releases or SEC filings, the question is, why?
The answer is relatively simple. An independent equity research firm, known as Traders News Source, issued a report surrounding the company. The report focused on the pipeline and progress made at JAGX.
In particular, the report centered around Mytesi. The product was developed by the company’s wholly-owned subsidiary Napo Pharmaceuticals. Today, Mytesi is approved by the FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on atiretroviral therapy.
The equity research firm sees quite a bit of value in JAGX as a result of Mytesi. The lead ingredient in the drug, Crofelemer, is a botanical drug extracted and purified from the red bark sap of the medicinal Croton lechleri tree. The tree is commonly found in the Amazon Rainforest.
According to Traders News Source, Napo has established a sustainable harvest program for the active ingredient. A program that ensures a high degree of quality while maintaining ecological integrity.
